Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Charting the Course in Myeloma: Durie Keeps Standards, New Goals in Sight

June 10th 2013

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.

Breakthrough Designation Granted to Daratumumab for Double Refractory Multiple Myeloma

May 1st 2013

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

Dr. Landgren on the Standard of Care in Multiple Myeloma

April 29th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with multiple myeloma.

Dr. Landgren on Carfilzomib and Pomalidomide

April 10th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.

Using the New Therapeutic Options in Multiple Myeloma

April 5th 2013

There have been waves of advancements in the treatment of multiple myeloma and further exploration of existing regimens and research into novel therapeutics hold the promise of advances.

Dr. Berenson Discusses New Potential Targets in Myeloma

April 4th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, comments on new potential targets in myeloma.

Dr. Landgren Discusses Risk and Treatment in Myeloma

March 28th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

Dr. Berenson on Carfilzomib in Refractory Multiple Myeloma

March 15th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

Making Time for Innovation: Myeloma Expert Sets Brisk Pace of Discovery

March 11th 2013

Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.

Putting the Focus on p53 in Multiple Myeloma

March 7th 2013

Shaji K. Kumar, MD, is working to understand the genomic intricacies of multiple myeloma, particularly the role played by activity associated with the TP53 gene.

Dr. Zelenetz on Treating Hematologic Malignancies

March 6th 2013

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

Dr. Landgren on Maintenance Therapy in Myeloma

February 25th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Pomalidomide Approved for Relapsed or Refractory Multiple Myeloma

February 8th 2013

The FDA announced the approval of pomalidomide for the treatment of multiple myeloma after patients have relapsed or become refractory to other cancer drugs.

Dr. Berenson on Pomalidomide Plus Doxil in Multiple Myeloma

February 6th 2013

James R. Berenson, MD, discusses a phase I/II study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma.

Dr. Jagannath on Life Expectancy in Myeloma

January 22nd 2013

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details the advances in life expectancy for patients with multiple myeloma.

Dr. Brian Durie on Novel Therapies in Multiple Myeloma

January 15th 2013

Brian G. M. Durie, MD, Cedars-Sinai Medical Center, Senior Advisor, Hematologic Malignancies, National Program Director, Multiple Myeloma and Related Disorders for Aptium Oncology, discusses novel therapies for multiple myeloma.

Emerging Agents in Multiple Myeloma: An Overview

January 2nd 2013

More potent versions of existing therapies are currently under development and showing considerable promise in early clinical trials for patients with multiple myeloma.

Dr. Jagannath on Pomalidomide in Multiple Myeloma

December 21st 2012

Sundar Jagannath, MD, discusses the use of pomalidomide (POM) in relapsed or refractory multiple myeloma.

Pomalidomide Labeled an Advance in Multiple Myeloma

December 10th 2012

The combination of pomalidomide and a steroid significantly improved outcomes for patients with MM who have exhausted other novel therapies, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.

MLN9708 May be Alternative to Bortezomib in Multiple Myeloma

December 10th 2012

MLN9708 has shown comparable efficacy and greater convenience and tolerability than bortezomib, for patients with multiple myeloma.